We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 551

Pfizer case shows protecting your own position isn't anti-competitive
  • Clayton Utz
  • Australia
  • March 2 2015

Commercial strategies and practices used by Pfizer to counter the expected loss of revenue caused by the expiry of its patent over Lipitor, its


ACCC v Pfizer some guidance to pharmaceutical companies on navigating competition risk
  • Herbert Smith Freehills LLP
  • Australia
  • March 3 2015

In brief The Federal Court of Australia has recently dismissed the ACCC’s case against pharmaceutical company Pfizer. The ACCC alleged that Pfizer had


ACCC v Pfizer some guidance to pharmaceutical companies on navigating competition risk
  • Herbert Smith Freehills LLP
  • Australia
  • March 3 2015

The Federal Court of Australia has recently dismissed the ACCC’s case against pharmaceutical company Pfizer. The ACCC alleged that Pfizer had misused


By the numbers
  • King & Wood Mallesons
  • Australia
  • August 13 2014

The CMA has seen a decline in the overall number of merger decisions in the past year. It made 65 phase 1 merger decisions in 2013-14, down from 100


Harper Review - implications for the private health insurance industry
  • DLA Piper LLP
  • Australia
  • April 10 2015

On 31 March 2015 the final report of the Competition Policy Review Panel chaired by Professor Ian Harper (Harper Review) was released. The Harper


ACCC imposes strict transparency provisions on updated Medicines Australia Code of Conduct
  • King & Wood Mallesons
  • Australia
  • October 28 2014

Roll-out of a new edition of Medicines Australia’s Code of Conduct has struck a roadblock, with the ACCC requesting that Medicines Australia amend


ACCC v Pfizer judgment summary and ramifications
  • Piper Alderman
  • Australia
  • February 27 2015

On 25 February 2015, Justice Flick of the Federal Court of Australia ruled in favour of Pfizer Australia Pty Ltd (Pfizer), dismissing the Australian


Australian Federal Court decides protecting your brand against generic pharmaceuticals is not a misuse of market power
  • Bird & Bird
  • Australia
  • March 18 2015

In a decision which will be welcomed by many pharmaceutical companies the Federal Court of Australia recently dismissed proceedings instituted by the


ACCC proposes to reauthorise collective negotiations by rural doctors
  • Corrs Chambers Westgarth
  • Australia
  • September 11 2013

On 28 August 2013, the ACCC issued a draft determination proposing to allow the Rural Doctors Association of Australia (RDAA) and its state


Below cost pricing?
  • King & Wood Mallesons
  • Australia
  • September 1 2014

According to reports in Friday's Australian FianancialRreview, (Hannah Low, page 32), the ACCC has sought to widen its claim against Pfizer. We